# Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma

> **NCT06567600** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 43 (estimated)

## Conditions studied

- Intrahepatic Cholangiocarcinoma
- Chemotherapy Effect
- Immunotherapy

## Interventions

- **DRUG:** Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody

## Key facts

- **NCT ID:** NCT06567600
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2024-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567600, "Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06567600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*